Recombinant alpha-fetoprotein - rEVO Biologics/Merrimack

Drug Profile

Recombinant alpha-fetoprotein - rEVO Biologics/Merrimack

Alternative Names: ABI-001; AFP - GTC/Merrimack; MM-093; Recombinant human alpha fetoprotein; rhAFP - GTC/Merrimack

Latest Information Update: 21 Feb 2013

Price : $50

At a glance

  • Originator Atlantic Pharmaceuticals
  • Developer Merrimack Pharmaceuticals
  • Class Alpha fetoproteins; Recombinant proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis

Highest Development Phases

  • Discontinued Multiple sclerosis; Myasthenia gravis; Psoriasis; Rheumatoid arthritis; Uveitis

Most Recent Events

  • 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
  • 11 Mar 2011 Discontinued - Phase-I for Multiple sclerosis in United Kingdom (SC)
  • 11 Mar 2011 Discontinued - Phase-I for Myasthenia gravis in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top